Provided by Tiger Fintech (Singapore) Pte. Ltd.

Genprex, Inc.

0.3629
-0.1126-23.68%
Post-market: 0.36300.0001+0.03%19:59 EDT
Volume:51.68M
Turnover:20.73M
Market Cap:15.57M
PE:-0.14
High:0.4138
Open:0.3372
Low:0.3351
Close:0.4755
52wk High:3.97
52wk Low:0.1400
Shares:42.91M
Float Shares:42.80M
Volume Ratio:0.25
T/O Rate:120.75%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.5758
EPS(LYR):-5.3391
ROE:-612.30%
ROA:-207.41%
PB:11.19
PE(LYR):-0.07

Loading ...

Genprex Inc - to Effect 1:50 Reverse Stock Split on Oct 21, 2025 - SEC Filing

THOMSON REUTERS
·
Oct 17

Gold Gains Over 1%; Abbott Shares Fall After Q3 Results

Benzinga
·
Oct 16

Genprex (GNPX) Shares Jump 41% After Hours Following New Cancer Therapy Data

Benzinga
·
Oct 15

Genprex Announces Positive Preclinical Data for Reqorsa® Gene Therapy in ALK-EML4 Positive Lung Cancer at 2025 Conference

Reuters
·
Oct 14

Genprex files to sell 25M shares of common stock for holders

TIPRANKS
·
Sep 13

Genprex Inc. Faces Potential Nasdaq Delisting Due to Non-Compliance with Stockholders' Equity Requirement

Reuters
·
Aug 21

Genprex Inc. Receives Notice of Allowance for Patents on Reqorsa® Gene Therapy with PD-L1 and PD-1 Antibodies to Combat Cancers

Reuters
·
Aug 18

Genprex Inc. Conducted Annual Stockholders Meeting

Reuters
·
Aug 16

Genprex Q2 EPS $(0.17) Beats $(0.42) Estimate

Benzinga
·
Aug 15

Genprex Inc. Reports Significant Deviation from Forecast with Lower Sales and Increased Net Loss in Latest Results

Reuters
·
Aug 04

BRIEF-Genprex Issues Stockholder Letter And Provides 2025 Corporate Update

Reuters
·
Aug 04

Genprex Inc. Announces New Progress in Lung Cancer Clinical Trials and Outlines Key Milestones for 2025

Reuters
·
Aug 04

Genprex Inc. Announces Promising Preclinical Results for Diabetes Gene Therapy GPX-002 at 2025 ADA Scientific Sessions

Reuters
·
Jun 24

Genprex Announces Promising Preclinical Results for Novel Diabetes Gene Therapy Using Non-Viral Lipid Nanoparticle Delivery System at 2025 ADA Conference

Reuters
·
Jun 23

Genprex Files for Resale of 15 Million Shares

MT Newswires Live
·
Jun 12

Genprex Inc. Enters $12.5 Million Share Purchase Agreement with Lincoln Park Capital

Reuters
·
Jun 12

Genprex Inc. Regains Compliance with Nasdaq Stockholders' Equity Requirement, Still Faces Minimum Bid Price Challenge

Reuters
·
Jun 09

Genprex Inc. Announces Phase 1/2 Clinical Trial of Quaratusugene Ozeplasmid Gene Therapy for Small Cell Lung Cancer

Reuters
·
Jun 03

Genprex Inc. to Participate in BIO International Convention in Boston

Reuters
·
Jun 03

Genprex Inc. Announces Promising Preclinical Results for Novel Diabetes Gene Therapy at ASGCT Annual Meeting

Reuters
·
May 28